

# BD CD3 (SK7)

## Monoclonal Antibodies Detecting Human Antigens

Form	Catalog number	Form	Catalog number	Form	Catalog number
Pure	347340	APC	340440	V450	652355
PE	347347	APC-R700	659119	V500-C	647453
PerCP-Cy5.5	340949	APC-Cy7	341090		
PerCP	347344	APC-H7	641397		
PE-Cy7	341091	AmCyan	339186		

Product availability varies by region. Contact BD Customer Support or your local sales representative for information.

## Research Applications

Research applications include:

- Study of in vitro activation of T lymphocytes<sup>1</sup>
- Examination of the CD3 complex in relation to the T-cell receptor (TCR)<sup>2</sup>
- Enumeration of T lymphocytes and T-lymphocyte subsets in peripheral blood<sup>3,4</sup>
- Investigation into the cytokine response<sup>5,6</sup>
- Research on the immune response<sup>7,8</sup>

## Description

### Specificity

The CD3 antibody reacts with the epsilon chain of the CD3 antigen/TCR complex.<sup>9</sup> This complex is composed of at least six proteins that range in molecular weight from 20 to 30 kilodaltons (kDa).<sup>10</sup> The antigen recognized by CD3 antibodies is noncovalently associated with either  $\alpha/\beta$  or  $\gamma/\delta$  TCR (70 to 90 kDa).<sup>11</sup>

### Antigen distribution

The CD3 antigen is present on 61% to 85% of normal peripheral blood lymphocytes,<sup>12</sup> 60% to 85% of thymocytes,<sup>13</sup> and on Purkinje cells in the cerebellum.<sup>14</sup>

This antibody has a mitogenic effect on most peripheral blood T lymphocytes, provided appropriate functional monocytes are present.<sup>1</sup>

### Clone

The CD3 antibody, clone SK7,<sup>15,16</sup> is derived from the hybridization of NS-1 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with human thymocytes.

### Composition

The CD3 antibody is composed of mouse IgG<sub>1</sub> heavy chains and kappa light chains.

**For Research Use Only. Not for use in diagnostic or therapeutic procedures.**

## Product configuration

The following are supplied in buffer containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μL)	Amount provided (μg)	Total volume (mL)	Concentration (μg/mL)	Stabilizer	Preservative
Pure	100	20	12.5	2	6.25	Gelatin	0.1% Sodium azide
PE	100	20	25	2	12.5	Gelatin	0.1% Sodium azide
PerCP-Cy5.5	50	20	3	1	3	Gelatin	0.1% Sodium azide
PerCP	100	20	25	2	12.5	Gelatin	0.1% Sodium azide
PE-Cy7	100	5	12.5	0.5	25	Gelatin	0.1% Sodium azide
APC	100	5	25	0.5	50	Gelatin	0.1% Sodium azide
APC-R700 <sup>a</sup>	100	5	12.5	0.5	25	BSA	CMT/MIT (3:1)
APC-Cy7	100	5	12.5	0.5	25	Gelatin	0.1% Sodium azide
APC-H7	100	5	50	0.5	100	BSA	CMT/MIT (3:1)
AmCyan	100	5	50	0.5	100	BSA	0.1% Sodium azide
V450 <sup>a</sup>	100	5	25	0.5	50	Gelatin	0.1% Sodium azide
V500-C <sup>a</sup>	100	5	25	0.5	50	BSA	MIT

<sup>a</sup> BD Horizon™ APC-R700, BD Horizon™ V450, BD Horizon™ V500-C

**CAUTION** Some APC-Cy7 conjugates, and to a lesser extent PE-Cy7, APC-H7, and APC-R700 conjugates, show changes in their emission spectra with prolonged exposure to paraformaldehyde or light. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.

**CAUTION** Prolonged exposure of cells to paraformaldehyde can lead to increased autofluorescence in the violet channels. For overnight storage of stained cells, wash and resuspend in buffer without paraformaldehyde after 1 hour of fixation.


## Procedure

Go to our website ([bdbiosciences.com](http://bdbiosciences.com)) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

## Representative Data

Flow cytometric analysis was performed on whole blood stained with the indicated conjugated antibody. Laser excitation was at 405 nm, 488 nm, 635 nm, or 640 nm.

The APC-R700 conjugate is read off the red laser (640 nm) using a 685 longpass mirror with a 712/21 bandpass filter. Representative data analyzed with a BD flow cytometer is shown in the following plots.



## Handling and Storage


Store vials at 2–8 °C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

## Warning

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection<sup>17,18</sup> and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

The APC-H7 conjugate contains a mixture of 0.00236% 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H -isothiazol-3-one [CMIT/MIT (3:1)], CAS number 55965-84-9. The APC-R700 conjugate contains a mixture of 0.00279% 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H -isothiazol-3-one [CMIT/MIT (3:1)], CAS

number 55965-84-9. The V500-C conjugate contains 0.0091% 2-methyl-4-isothiazolin-3-one (MIT), CAS number 2682-20-4. The AmCyan conjugate contains 0.3958% ethylenediamine, ethoxylated and propoxylated, CAS number 26316-40-5. These reagents are classified as hazardous according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS).

	<b>Warning</b>
	H317: May cause an allergic skin reaction. H412: Harmful to aquatic life with long lasting effects.
<b>Prevention</b>	P261: Avoid breathing dust/fume/gas/mist/vapors/spray. P272: Contaminated work clothing should not be allowed out of the workplace. P280: Wear protective gloves/protective clothing/eye protection/face protection. P273: Avoid release to the environment.
<b>Response</b>	P302+P352: IF ON SKIN: Wash with plenty of water. P333+P313: If skin irritation or rash occurs: Get medical advice/attention. P321: Specific treatment (see Safety Data Sheet). P362+P364: Take off contaminated clothing and wash it before reuse.
<b>Disposal</b>	P501: Dispose of contents/container to an approved facility in accordance with local, regional, national and international regulations.

Go to [regdocs.bd.com](http://regdocs.bd.com) to download the Safety Data Sheet.

## Characterization

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent.

## Warranty

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

## References

1. Kaneoka H, Perez-Rojas G, Sasasuki T, Benike CJ, Engleman EG. Human T lymphocyte proliferation induced by a pan-T monoclonal antibody (anti-Leu-4): heterogeneity of response is a function of monocytes. *J Immunol.* 1983;131:158-164.
2. Allison JP, Lanier LL. Structure, function, and serology of the T-cell antigen receptor complex. *Ann Rev Immunol.* 1987;5:503-540.
3. Friedrich W, O'Reilly RJ, Kozinger B, Gebhard DF, Good RA, Evans RL. T lymphocyte reconstitution in recipients of bone marrow transplants with and without GVHD: imbalances of T-cell subpopulations having unique regulatory and cognitive functions. *Blood.* 1982;59:696-701.

4. Kurrle R. Cluster report: CD3. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:290-293.
5. Maecker HT, Maino VC. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. *Hum Immunol*. 2004;65:493-499.
6. Maino VC, Picker LJ. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. *Cytometry*. 1998;34:207-215.
7. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Immune dysfunction and micrometastases in women with breast cancer. *Breast Cancer Res Treat*. 2005;91:163-171.
8. Tu W, Chen S, Sharp M, et al. Persistent and selective deficiency of CD4<sup>+</sup> T cell immunity to cytomegalovirus in immunocompetent young children. *J Immunol*. 2004;172:3260-3267.
9. van Dongen JJM, Krissansen GW, Wolvers-Tettero ILM, et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. *Blood*. 1988;71:603-612.
10. Brenner MB, Groh V, Porcelli SA, et al. Structure and distribution of the human  $\gamma/\delta$  T-cell receptor. In: Knapp W, Dörken B, Gilks WR, et al, eds. *Leucocyte Typing IV: White Cell Differentiation Antigens*. New York, NY: Oxford University Press; 1989:1049-1053.
11. Clevers H, Alarcón B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. *Annu Rev Immunol*. 1988;6:629-662.
12. Reichert T, DeBruyère M, Deney V, et al. Lymphocyte subset reference ranges in adult Caucasians. *Clin Immunol Immunopathol*. 1991;60:190-208.
13. Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. *J Immunol*. 1986;137:2501-2507.
14. Garson JA, Beverley PCL, Coakham HB, Harper EI. Monoclonal antibodies against human T lymphocytes label Purkinje neurones of many species. *Nature*. 1982;298:375-377.
15. Haynes BF. Summary of T-cell studies performed during the Second International Workshop and Conference on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. *Leukocyte Typing II: Human T Lymphocytes*. Vol 1. New York, NY: Springer-Verlag; 1986:3-30.
16. Knowles RW. Immunochemical analysis of the T-cell-specific antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. *Leukocyte Typing II: Human T Lymphocytes*. Vol 1. New York, NY: Springer-Verlag; 1986:259-288.
17. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline—Fourth Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2014. CLSI document M29-A4.
18. Centers for Disease Control and Prevention. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings.  
<https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html>. Accessed March 12, 2019.

## Patents and Trademarks

For US patents that may apply, see [bd.com/patents](https://bd.com/patents).

BD, the BD Logo and Horizon are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2024 BD. All rights reserved.

Cy™ is a trademark of GE Healthcare. This product is subject to proprietary rights of GE Healthcare and Carnegie Mellon University, and is made and sold under license from GE Healthcare. This product is licensed for sale only for research. It is not licensed for any other use. If you require a commercial license to use this product and do not have one, return this material, unopened, to BD Biosciences, 155 North McCarthy Boulevard, Milpitas, California 95035, and any money paid for the material will be refunded.

## Contact Information

**Becton, Dickinson and Company**

**BD Biosciences**

155 North McCarthy Boulevard

Milpitas, California 95035 USA

[bdbiosciences.com](https://bdbiosciences.com)

[ResearchApplications@bd.com](mailto:ResearchApplications@bd.com)